Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro

FEMS Immunology and Medical Microbiology

Volumn 65, Issue 2, 2012, Pages 395-398

  Ryan, Elizabeth M ^a   Alkawareek, Mahmoud Y ^a   Donnelly, Ryan F ^a   Gilmore, Brendan F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Biofilm; Biofilm eradication; Cefotaxime; Escherichia coli; Phage therapy; Phage antibiotic synergy; T4 bacteriophage

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIOPHAGE T4; BIOFILM; CONCENTRATION (PARAMETERS); CULTURE MEDIUM; DRUG POTENTIATION; ERADICATION THERAPY; ESCHERICHIA COLI; IN VITRO STUDY; NONHUMAN; PHAGE ANTIBIOTIC SYNERGY; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIOPHAGE T4; BIOFILMS; BIOLOGICAL AGENTS; CEFOTAXIME; DRUG SYNERGISM; ESCHERICHIA COLI; HUMANS; VIRAL PLAQUE ASSAY;

EID: 84862687253     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2012.00977.x     Document Type: Article

References (16)

1. Abedon ST (1992) Lysis of lysis-inhibited bacteriophage T4-infected cells. J Bacteriol 174: 8073-8080.
2. Abedon ST (2006) Phage ecology. The Bacteriophages (Calendar R & Abedon ST eds), pp. 37-46. Oxford University Press, Oxford.
3. Andrews JM (2001) Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48: 5-16.
4. Bedi MS, Verma V & Chhibber S (2009) Amoxicillin and specific bacteriophage can be used together for eradication of biofilm of Klebsiella pneumoniae B5055. World J Microbiol Biotechnol 25: 1145-1151.
5. Carson L, Gorman SP & Gilmore BF (2010) The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol Med Microbiol 59: 447-455.
6. Ceri H, Olson ME, Stremick C, Read RR, Morck D & Buret A (1999) The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms. J Clin Microbiol 37: 1771-1776.
7. Comeau AM, Tétart F, Trojet SN, Prère MF & Krisch HM (2007) Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. D. Fox, ed. PLoS ONE, 2: e799.
8. Corbin BD, McLean RJ & Aron GM (2001) Bacteriophage T4 multiplication in a glucose-limited Escherichia coli biofilm. Can J Microbiol 47: 680-684.
9. Curtin JJ & Donlan RM (2006) Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 50: 1268-1275.
10. Doermann AH (1952) The Intracellular Growth of Bacteriophages: I. Liberation of intracellular bacteriophage T4 by premature lysis with another phage or with cyanide. J Gen Physiol 35: 645-656.
11. Donlan RM (2009) Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol 17: 66-72.
12. Hanlon GW (2007) Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 30: 118-128.
13. Ryan EM, Gorman SP, Donnelly RF & Gilmore BF (2011) Recent advances in phage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol 63: 1253-1264.
14. Santos SB, Carvalho CM, Sillankorva S, Nicolau A, Ferreira EC & Azeredo J (2009) The use of antibiotics to improve phage detection and enumeration by the double-layer agar technique. BMC Microbiol 9: 148.
15. Sharma M, Ryu JH & Beuchat LR (2005) Inactivation of Escherichia coli O157:H7 in biofilm on stainless steel by treatment with an alkaline cleaner and a bacteriophage. J Appl Microbiol 99: 449-459.
16. Weld RJ, Butts C & Heinemann JA (2004) Models of phage growth and their applicability to phage therapy. J Theor Biol 227: 1-11.